MINI FUTURE OPTIONSSCHEIN CALL - EVOTEC Share Price

Certificat

DE000DG2K3K4

Market Closed - Börse Stuttgart 09:40:01 03/05/2024 pm IST
6.57 EUR -1.20% Intraday chart for MINI FUTURE OPTIONSSCHEIN CALL - EVOTEC
Current month+1.39%
1 month-38.19%
Date Price Change Volume
03/24/03 6.57 -1.20% 0
02/24/02 6.65 +2.62% 0
30/24/30 6.48 +1.09% 0
29/24/29 6.41 +5.95% 0
26/24/26 6.05 +2.02% 0

Delayed Quote Börse Stuttgart

Last update May 03, 2024 at 09:40 pm IST

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellCALL
Underlying EVOTEC SE
Issuer DZ BANK
WKN DG2K3K
ISINDE000DG2K3K4
Date issued 23/10/2014
Strike 3.341
Maturity Unlimited
Parity 1 : 1
Emission price 0.286
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 42.6
Lowest since issue 0.15

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.76 EUR
Average target price
23.94 EUR
Spread / Average Target
+145.29%
Consensus